<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>spironolactone</title><link>http://www.unboundmedicine.com/medline/ebm/research/spironolactone</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19926893/full_citation/Addition_of_Angiotensin_Receptor_Blockade_or_Mineralocorticoid_Antagonism_to_Maximal_Angiotensin_Converting_Enzyme_Inhibition_in_Diabetic_Nephropathy_</link><description>Mehdi UF, Adams-Huet B, Raskin P, et al. <br/><span class="title">Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of the American Society of Nephrology : JASN">J Am Soc Nephrol 2009 Nov 19.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19926893/abstract/Addition_of_Angiotensin_Receptor_Blockade_or_Mineralocorticoid_Antagonism_to_Maximal_Angiotensin_Converting_Enzyme_Inhibition_in_Diabetic_Nephropathy_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19926893/full_citation/Addition_of_Angiotensin_Receptor_Blockade_or_Mineralocorticoid_Antagonism_to_Maximal_Angiotensin_Converting_Enzyme_Inhibition_in_Diabetic_Nephropathy_">Full Citation</a></description></item><item><title>Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19925284/full_citation/Antifibrotic_Effects_of_Aldosterone_Receptor_Blocker__Spironolactone__in_Patients_with_Chronic_Kidney_Disease_</link><description>Guney I, Selcuk NY, Altintepe L, et al. <br/><span class="title">Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease. [JOURNAL ARTICLE]</span><br/><span class="source" title="Renal failure">Ren Fail 2009 Jan; 31(9):779-784.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19925284/abstract/Antifibrotic_Effects_of_Aldosterone_Receptor_Blocker__Spironolactone__in_Patients_with_Chronic_Kidney_Disease_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19925284/full_citation/Antifibrotic_Effects_of_Aldosterone_Receptor_Blocker__Spironolactone__in_Patients_with_Chronic_Kidney_Disease_">Full Citation</a></description></item><item><title>A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19922777/full_citation/A_continuous_and_highly_effective_static_mixing_process_for_antisolvent_precipitation_of_nanoparticles_of_poorly_water_soluble_drugs_</link><description>Dong Y, Ng WK, Hu J, et al. <br/><span class="title">A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. [JOURNAL ARTICLE]</span><br/><span class="source" title="International journal of pharmaceutics">Int J Pharm 2009 Nov 13.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19922777/abstract/A_continuous_and_highly_effective_static_mixing_process_for_antisolvent_precipitation_of_nanoparticles_of_poorly_water_soluble_drugs_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19922777/full_citation/A_continuous_and_highly_effective_static_mixing_process_for_antisolvent_precipitation_of_nanoparticles_of_poorly_water_soluble_drugs_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19922777/A_continuous_and_highly_effective_static_mixing_process_for_antisolvent_precipitation_of_nanoparticles_of_poorly_water_soluble_drugs_">Find Related Articles</a> </description></item><item><title>Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19915794/full_citation/Torsades_de_Pointes_induced_by_a_combination_of_garenoxacin_and_disopyramide_and_other_cytochrome_P450_family_3_subfamily_A_polypeptide_4_influencing_drugs_during_hypokalemia_due_to_licorice_</link><description>Miyamoto K, Kawai H, Aoyama R, et al. <br/><span class="title">Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice. [JOURNAL ARTICLE]</span><br/><span class="source" title="Clinical and experimental nephrology">Clin Exp Nephrol 2009 Nov 14.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19915794/abstract/Torsades_de_Pointes_induced_by_a_combination_of_garenoxacin_and_disopyramide_and_other_cytochrome_P450_family_3_subfamily_A_polypeptide_4_influencing_drugs_during_hypokalemia_due_to_licorice_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19915794/full_citation/Torsades_de_Pointes_induced_by_a_combination_of_garenoxacin_and_disopyramide_and_other_cytochrome_P450_family_3_subfamily_A_polypeptide_4_influencing_drugs_during_hypokalemia_due_to_licorice_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19915794/Torsades_de_Pointes_induced_by_a_combination_of_garenoxacin_and_disopyramide_and_other_cytochrome_P450_family_3_subfamily_A_polypeptide_4_influencing_drugs_during_hypokalemia_due_to_licorice_">Find Related Articles</a> </description></item><item><title>Secondary adrenal insufficiency and primary antiphospholipid syndrome.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19915297/full_citation/Secondary_adrenal_insufficiency_and_primary_antiphospholipid_syndrome_</link><description>Alfadhli EM <br/><span class="title">Secondary adrenal insufficiency and primary antiphospholipid syndrome. [Journal Article]</span><br/><span class="source" title="Internal medicine (Tokyo, Japan)">Intern Med 2009; 48(22):1963-6.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19915297/abstract/Secondary_adrenal_insufficiency_and_primary_antiphospholipid_syndrome_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19915297/full_citation/Secondary_adrenal_insufficiency_and_primary_antiphospholipid_syndrome_">Full Citation</a></description></item><item><title>Autonomic cardiovascular modulation.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19914892/full_citation/Autonomic_cardiovascular_modulation_</link><description>Tobaldini E, Montano N, Wei SG, et al. <br/><span class="title">Autonomic cardiovascular modulation. [Journal Article]</span><br/><span class="source" title="IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine &amp; Biology Society">IEEE Eng Med Biol Mag 2009 Nov-Dec; 28(6):79-85.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19914892/abstract/Autonomic_cardiovascular_modulation_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19914892/full_citation/Autonomic_cardiovascular_modulation_">Full Citation</a></description></item><item><title>Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19913415/full_citation/Attenuation_of_adverse_cardiac_effects_in_prednisolone_treated_delta_sarcoglycan_deficient_mice_by_mineralocorticoid_receptor_antagonism_</link><description>Bauer R, Blain A, Greally E, et al. <br/><span class="title">Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. [JOURNAL ARTICLE]</span><br/><span class="source" title="Neuromuscular disorders : NMD">Neuromuscul Disord 2009 Nov 11.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19913415/abstract/Attenuation_of_adverse_cardiac_effects_in_prednisolone_treated_delta_sarcoglycan_deficient_mice_by_mineralocorticoid_receptor_antagonism_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19913415/full_citation/Attenuation_of_adverse_cardiac_effects_in_prednisolone_treated_delta_sarcoglycan_deficient_mice_by_mineralocorticoid_receptor_antagonism_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19913415/Attenuation_of_adverse_cardiac_effects_in_prednisolone_treated_delta_sarcoglycan_deficient_mice_by_mineralocorticoid_receptor_antagonism_">Find Related Articles</a> </description></item><item><title>Spironolactone Therapy in Heart Failure Patients with Chronic Kidney Disease.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19911355/full_citation/Spironolactone_Therapy_in_Heart_Failure_Patients_with_Chronic_Kidney_Disease_</link><description>Lopes R, Lourenco P, Mascarenhas J, et al. <br/><span class="title">Spironolactone Therapy in Heart Failure Patients with Chronic Kidney Disease. [JOURNAL ARTICLE]</span><br/><span class="source" title="Clinical cardiology">Clin Cardiol 2009 Nov 12; 32(10):597.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19911355/full_citation/Spironolactone_Therapy_in_Heart_Failure_Patients_with_Chronic_Kidney_Disease_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19911355/Spironolactone_Therapy_in_Heart_Failure_Patients_with_Chronic_Kidney_Disease_">Find Related Articles</a> </description></item><item><title>Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19909979/full_citation/Modulation_of_the_mineralocorticoid_receptor_as_add_on_treatment_in_depression:_A_randomized_double_blind_placebo_controlled_proof_of_concept_study_</link><description>Otte C, Hinkelmann K, Moritz S, et al. <br/><span class="title">Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of psychiatric research">J Psychiatr Res 2009 Nov 10.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19909979/abstract/Modulation_of_the_mineralocorticoid_receptor_as_add_on_treatment_in_depression:_A_randomized_double_blind_placebo_controlled_proof_of_concept_study_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19909979/full_citation/Modulation_of_the_mineralocorticoid_receptor_as_add_on_treatment_in_depression:_A_randomized_double_blind_placebo_controlled_proof_of_concept_study_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19909979/Modulation_of_the_mineralocorticoid_receptor_as_add_on_treatment_in_depression:_A_randomized_double_blind_placebo_controlled_proof_of_concept_study_">Find Related Articles</a> </description></item><item><title>Development and validation of an HPLC method for the simultaneous analysis of 23 selected drugs belonging to different therapeutic groups in human urine samples.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19907087/full_citation/Development_and_validation_of_an_HPLC_method_for_the_simultaneous_analysis_of_23_selected_drugs_belonging_to_different_therapeutic_groups_in_human_urine_samples_</link><description>Baranowska I, Markowski P, Baranowski J <br/><span class="title">Development and validation of an HPLC method for the simultaneous analysis of 23 selected drugs belonging to different therapeutic groups in human urine samples. [Journal Article, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="Analytical sciences : the international journal of the Japan Society for Analytical Chemistry">Anal Sci 2009 Nov; 25(11):1307-13.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19907087/abstract/Development_and_validation_of_an_HPLC_method_for_the_simultaneous_analysis_of_23_selected_drugs_belonging_to_different_therapeutic_groups_in_human_urine_samples_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19907087/full_citation/Development_and_validation_of_an_HPLC_method_for_the_simultaneous_analysis_of_23_selected_drugs_belonging_to_different_therapeutic_groups_in_human_urine_samples_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19907087/Development_and_validation_of_an_HPLC_method_for_the_simultaneous_analysis_of_23_selected_drugs_belonging_to_different_therapeutic_groups_in_human_urine_samples_">Find Related Articles</a> </description></item></channel></rss>